New developments in psychopharmacology of attention deficit hyperactivity disorder

Producción científica: Review articlerevisión exhaustiva

12 Citas (Scopus)


Stimulants have been the mainstay of the psychopharmacological treatment of attention deficit hyperactivity disorder (ADHD) for over 60 years. In the last 5 years, there have been a number of important developments in terms of potential new treatments for ADHD. Since stimulants have such a short half-life, considerable research has focused on the development of new delivery systems that will allow once-a-day dosing. New formulations of both amphetamine (AMP) and methylphenidate (MPH) have appeared which differ in terms of their optical isomers from the commonly used compounds. A wide variety of compounds are currently in development as therapeutic agents for ADHD. Some, like the stimulants, primarily impact the noradrenergic and dopaminergic neurotransmitter systems, while others have novel effects on the cholinergic, histaminergic and peptidergic systems. Advances in the pharmacogenetics of ADHD may lead to the development of yet more compounds in the near future.

Idioma originalEnglish (US)
Páginas (desde-hasta)1797-1807
Número de páginas11
PublicaciónExpert Opinion on Investigational Drugs
EstadoPublished - 2001

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Profundice en los temas de investigación de 'New developments in psychopharmacology of attention deficit hyperactivity disorder'. En conjunto forman una huella única.

Citar esto